Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Regulus Therapeutics (RLS) contingent value right may be worth $3-$4 a share in its planned sale to Novartis (NVS), according ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Novartis to acquire Regulus Therapeutics for up to $1.7B. Explore the deal details, premium pricing, and potential milestone ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis ...